Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes
Elisabetta Sauta(IRCCS Humanitas Research Hospital), Matteo Giovanni Della Porta(Humanitas University), Pierre Fenaux(Saint Louis University Hospital), Lorenzo Dall’Olio, Victor Savevski(Humanitas University), Alessia Campagna(Humanitas University), Matteo Zampini(IRCCS Humanitas Research Hospital), Gastone Castellani(University of Bologna), Erica Travaglino(Policlinico San Matteo Fondazione), Anne Sophie Kubasch(Leukemia and Lymphoma Society), Marilena Bicchieri(Humanitas University), Claudia Sala, Daniele Dall’Olio(University of Bologna), Torsten Haferlach(Martin Luther Christian University), Cristina Astrid Tentori(Humanitas University), Shahram Kordasti(Guy's Hospital), Gabriele Todisco(Humanitas University), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Amer M. Zeidan(Yale Cancer Center), Lin‐Pierre Zhao, Marta Ubezio(Humanitas University), Uwe Platzbecker(National Center for Tumor Diseases), Ettore Mosca(Construction Technologies Institute), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Gianluca Asti(IRCCS Humanitas Research Hospital), Elena Riva(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Saverio D’Amico(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k